{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:16:55Z","timestamp":1790144215411,"version":"4.0.1"},"reference-count":147,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T00:00:00Z","timestamp":1517788800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002066","name":"GlaxoSmithKline foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00153","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T04:24:14Z","timestamp":1517804654000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Current Status of Gene Engineering Cell Therapeutics"],"prefix":"10.3389","volume":"9","author":[{"given":"Aurore","family":"Saudemont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Jespers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Clay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,2,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1056\/NEJMoa1000164","article-title":"Efficacy of gene therapy for X-linked severe combined immunodeficiency","volume":"363","author":"Hacein-Bey-Abina","year":"2010","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1056\/NEJMoa0905955","article-title":"Limbal stem-cell therapy and long-term corneal regeneration","volume":"363","author":"Rama","year":"2010","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"97ra80","DOI":"10.1126\/scitranslmed.3002716","article-title":"Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci Transl Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/320232a0","article-title":"Transfer of specificity by murine alpha and beta T-cell receptor genes","volume":"320","author":"Dembic","year":"1986","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4049\/jimmunol.163.1.507","article-title":"Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity","volume":"163","author":"Clay","year":"1999","journal-title":"J Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nri841","article-title":"T-cell-receptor gene therapy","volume":"2","author":"Schumacher","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"B13","first-page":"2470","article-title":"Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes","volume":"63","author":"Pinthus","year":"2003","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"20140374","DOI":"10.1098\/rstb.2014.0374","article-title":"T cell engineering as therapy for cancer and HIV: our synthetic future","volume":"370","author":"June","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.ymthe.2017.03.034","article-title":"Chimeric antigen receptors: a cell and gene therapy perspective","volume":"25","author":"Riviere","year":"2017","journal-title":"Mol Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5852","DOI":"10.1158\/1078-0432.CCR-10-1280","article-title":"Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials","volume":"16","author":"Davis","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J Immunother"},{"key":"B21","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/1078-0432.CCR-13-3017","article-title":"Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma","volume":"20","author":"Chodon","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/annonc\/mdw378.29","article-title":"Open label non-randomized multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259 SPEAR T-cellsTM in HLA-A*02+ patients with synovial sarcoma (NCT01343043)","volume":"27","author":"Mackall","year":"2016","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood.V120.21.472.472","article-title":"Adoptive transfer of gene-modified T-cells engineered to express high-affinity TCRs for cancer-testis antigens (CTAs) NY-ESO-1 or Lage-1, in MM patients post auto-SCT","volume":"120","author":"Rapoport","year":"2012","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-14-1559","article-title":"Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer","volume":"21","author":"Kageyama","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V96.3.785","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood"},{"key":"B29","first-page":"467","article-title":"Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection","volume":"96","author":"Walker","year":"2000","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"132ra153","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1006\/mthe.2002.0611","article-title":"A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy","volume":"5","author":"Deeks","year":"2002","journal-title":"Mol Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"B41","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","article-title":"Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes","volume":"181","author":"Brocker","year":"1995","journal-title":"J Exp Med"},{"key":"B44","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V96.5.1999","article-title":"Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells","volume":"96","author":"Brocker","year":"2000","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","article-title":"Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors","volume":"10","author":"Kochenderfer","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"B47","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00262-014-1568-1","article-title":"Engineered T cells for cancer therapy","volume":"63","author":"June","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B48","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B49","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/cr.2016.154","article-title":"Driving gene-engineered T cell immunotherapy of cancer","volume":"27","author":"Johnson","year":"2017","journal-title":"Cell Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"B55","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/sj.bmt.1704086","article-title":"IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I\/II trial","volume":"32","author":"Burns","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1158\/1078-0432.CCR-03-0683","article-title":"Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial","volume":"10","author":"Krause","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"383","DOI":"10.7150\/jca.2.383","article-title":"Bortezomib treatment to potentiate the anti-tumor immunity of ex-vivo expanded adoptively infused autologous natural killer cells","volume":"2","author":"Lundqvist","year":"2011","journal-title":"J Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","article-title":"Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression","volume":"17","author":"Parkhurst","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12967-015-0632-8","article-title":"Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer","volume":"13","author":"Sakamoto","year":"2015","journal-title":"J Transl Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/CJI.0000000000000059","article-title":"Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients","volume":"38","author":"Szmania","year":"2015","journal-title":"J Immunother"},{"key":"B63","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.bcmd.2004.08.013","article-title":"IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation","volume":"33","author":"Koehl","year":"2004","journal-title":"Blood Cells Mol Dis"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/sj.leu.2403524","article-title":"Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation","volume":"18","author":"Passweg","year":"2004","journal-title":"Leukemia"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s00262-010-0896-z","article-title":"Allogeneic natural killer cells for refractory lymphoma","volume":"59","author":"Bachanova","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B66","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1182\/blood-2011-01-329508","article-title":"Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients","volume":"118","author":"Curti","year":"2011","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/bmt.2012.162","article-title":"Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers","volume":"48","author":"Stern","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","article-title":"Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein","volume":"123","author":"Bachanova","year":"2014","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br J Haematol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1365-2141.2008.07340.x","article-title":"Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation","volume":"143","author":"Shi","year":"2008","journal-title":"Br J Haematol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3109\/14653249.2010.515582","article-title":"A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer","volume":"13","author":"Geller","year":"2011","journal-title":"Cytotherapy"},{"key":"B73","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14653240802301872","article-title":"Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial","volume":"10","author":"Arai","year":"2008","journal-title":"Cytotherapy"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","article-title":"Treatment of patients with advanced cancer with the natural killer cell line NK-92","volume":"15","author":"Tonn","year":"2013","journal-title":"Cytotherapy"},{"key":"B75","doi-asserted-by":"publisher","first-page":"89256","DOI":"10.18632\/oncotarget.19204","article-title":"A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy","volume":"8","author":"Williams","year":"2017","journal-title":"Oncotarget"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jcyt.2017.07.008","article-title":"Phase 1 clinical trial of adoptive immunotherapy using \u201coff-the-shelf\u201d activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia","volume":"19","author":"Boyiadzis","year":"2017","journal-title":"Cytotherapy"},{"key":"B77","doi-asserted-by":"publisher","first-page":"17481","DOI":"10.1073\/pnas.0804788105","article-title":"Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas","volume":"105","author":"Kruschinski","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B78","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.1158\/1078-0432.CCR-08-2810","article-title":"2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells","volume":"15","author":"Altvater","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00262-007-0383-3","article-title":"Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells","volume":"57","author":"Muller","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"B81","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1158\/2326-6066.CIR-14-0114","article-title":"Targeting CD20+ aggressive B-cell non-Hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice","volume":"3","author":"Chu","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e26527","DOI":"10.4161\/onci.26527","article-title":"Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity","volume":"2","author":"Boissel","year":"2013","journal-title":"Oncoimmunology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e28147","DOI":"10.4161\/onci.28147","article-title":"Are natural killer cells superior CAR drivers?","volume":"3","author":"Klingemann","year":"2014","journal-title":"Oncoimmunology"},{"key":"B84","doi-asserted-by":"publisher","first-page":"11483","DOI":"10.1038\/srep11483","article-title":"CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells","volume":"5","author":"Han","year":"2015","journal-title":"Sci Rep"},{"key":"B85","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3389\/fimmu.2017.00774","article-title":"Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy","volume":"8","author":"Gao","year":"2017","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/sj.bjc.6690800","article-title":"Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma","volume":"81","author":"Schmidt-Wolf","year":"1999","journal-title":"Br J Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s00262-012-1260-2","article-title":"Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study","volume":"61","author":"Li","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2015.02.055","article-title":"Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma","volume":"148","author":"Lee","year":"2015","journal-title":"Gastroenterology"},{"key":"B89","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.imlet.2017.01.014","article-title":"2003-2013, a valuable study: autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer","volume":"183","author":"Lin","year":"2017","journal-title":"Immunol Lett"},{"key":"B90","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.18632\/oncotarget.12273","article-title":"Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea","volume":"8","author":"Kong","year":"2017","journal-title":"Oncotarget"},{"key":"B91","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40880-015-0002-1","article-title":"Cytokine-induced killer (CIK) cells: from basic research to clinical translation","volume":"34","author":"Guo","year":"2015","journal-title":"Chin J Cancer"},{"key":"B92","doi-asserted-by":"publisher","first-page":"238924","DOI":"10.1155\/2012\/238924","article-title":"Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells","volume":"2012","author":"Schlimper","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1038\/mt.2013.192","article-title":"Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 \u201csuper-stimulation\u201d","volume":"21","author":"Hombach","year":"2013","journal-title":"Mol Ther"},{"key":"B94","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bjh.12282","article-title":"Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor","volume":"161","author":"Tettamanti","year":"2013","journal-title":"Br J Haematol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s00262-015-1757-6","article-title":"Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies","volume":"64","author":"Ren","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B96","doi-asserted-by":"publisher","first-page":"66137","DOI":"10.18632\/oncotarget.19821","article-title":"Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children","volume":"8","author":"Merker","year":"2017","journal-title":"Oncotarget"},{"key":"B97","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1084\/jem.20021500","article-title":"Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells","volume":"197","author":"Gober","year":"2003","journal-title":"J Exp Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/mt.2012.267","article-title":"Bispecific T-cells expressing polyclonal repertoire of endogenous gammadelta T-cell receptors and introduced CD19-specific chimeric antigen receptor","volume":"21","author":"Deniger","year":"2013","journal-title":"Mol Ther"},{"key":"B99","doi-asserted-by":"publisher","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1182\/blood-2016-08-732636","article-title":"NY-ESO-1 TCR single edited central memory and memory stem T cells to treat multiple myeloma without inducing GvHD","volume":"130","author":"Mastaglio","year":"2017","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/mt.2013.59","article-title":"HLA engineering of human pluripotent stem cells","volume":"21","author":"Riolobos","year":"2013","journal-title":"Mol Ther"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","article-title":"Toward eliminating HLA class I expression to generate universal cells from allogeneic donors","volume":"122","author":"Torikai","year":"2013","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"21757","DOI":"10.1038\/srep21757","article-title":"Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application","volume":"6","author":"Torikai","year":"2016","journal-title":"Sci Rep"},{"key":"B104","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat Biotechnol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"17002","DOI":"10.18632\/oncotarget.15218","article-title":"A versatile system for rapid multiplex genome-edited CAR T cell generation","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0140-6736(03)14634-X","article-title":"Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines","volume":"362","author":"Peggs","year":"2003","journal-title":"Lancet"},{"key":"B108","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1365-2141.2006.06108.x","article-title":"Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation","volume":"134","author":"Feuchtinger","year":"2006","journal-title":"Br J Haematol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bcmd.2007.07.003","article-title":"Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells","volume":"40","author":"Mackinnon","year":"2008","journal-title":"Blood Cells Mol Dis"},{"key":"B110","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1182\/blood-2009-08-236356","article-title":"Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells","volume":"115","author":"Moosmann","year":"2010","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1182\/blood-2016-01-628982","article-title":"T cells for viral infections after allogeneic hematopoietic stem cell transplant","volume":"127","author":"Bollard","year":"2016","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1038\/leu.2017.16","article-title":"Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT","volume":"31","author":"Neuenhahn","year":"2017","journal-title":"Leukemia"},{"key":"B115","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1097\/MPH.0b013e3181bf5e2d","article-title":"Adoptive transfer of cytomegalovirus\/Epstein-Barr virus-specific immune effector cells for therapeutic and preventive\/preemptive treatment of pediatric allogeneic cell transplant recipients","volume":"32","author":"Dong","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/j.1365-2141.2011.08579.x","article-title":"Third-party virus-specific T cells eradicate adenoviraemia but trigger bystander graft-versus-host disease","volume":"154","author":"Qasim","year":"2011","journal-title":"Br J Haematol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol Ther"},{"key":"B118","doi-asserted-by":"publisher","first-page":"242ra283","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med"},{"key":"B119","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.jaci.2015.12.1311","article-title":"Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes","volume":"137","author":"Naik","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/bmt.2016.17","article-title":"Virus-specific T-cell banks for \u2018off the shelf\u2019 adoptive therapy of refractory infections","volume":"51","author":"O\u2019Reilly","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1172\/JCI1268","article-title":"Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation","volume":"101","author":"Asai","year":"1998","journal-title":"J Clin Invest"},{"key":"B123","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1182\/blood-2006-05-024315","article-title":"Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors","volume":"109","author":"Lundqvist","year":"2007","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","article-title":"NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects","volume":"115","author":"Olson","year":"2010","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/72303","article-title":"Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression","volume":"6","author":"Zhang","year":"2000","journal-title":"Nat Med"},{"key":"B126","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1084\/jem.20020029","article-title":"The immune regulatory function of lymphoproliferative double negative T cells in vitro and in vivo","volume":"196","author":"Ford","year":"2002","journal-title":"J Exp Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.trim.2010.11.003","article-title":"Adoptive transfer of DNT cells induces long-term cardiac allograft survival and augments recipient CD4(+)Foxp3(+) Treg cell accumulation","volume":"24","author":"Zhang","year":"2011","journal-title":"Transpl Immunol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nri2395","article-title":"Mesenchymal stem cells in health and disease","volume":"8","author":"Uccelli","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/scrt2","article-title":"Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications","volume":"1","author":"Ghannam","year":"2010","journal-title":"Stem Cell Res Ther"},{"key":"B130","doi-asserted-by":"publisher","first-page":"a015560","DOI":"10.1101\/cshperspect.a015560","article-title":"Mesenchymal stromal cells in transplantation rejection and tolerance","volume":"3","author":"English","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B131","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1046\/j.1365-2567.2002.01412.x","article-title":"Characterization of human CD25+ CD4+ T cells in thymus, cord and adult blood","volume":"106","author":"Wing","year":"2002","journal-title":"Immunology"},{"key":"B132","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fimmu.2012.00051","article-title":"Molecular mechanisms of Treg-mediated T cell suppression","volume":"3","author":"Schmidt","year":"2012","journal-title":"Front Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127\u2212 T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin Immunol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","article-title":"Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation","volume":"117","author":"Di Ianni","year":"2011","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fimmu.2014.00016","article-title":"Immunological outcome in haploidentical-HSC transplanted patients treated with IL-10-anergized donor T cells","volume":"5","author":"Bacchetta","year":"2014","journal-title":"Front Immunol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1182\/blood-2015-06-653667","article-title":"Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect","volume":"127","author":"Brunstein","year":"2016","journal-title":"Blood"},{"key":"B137","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clim.2014.03.016","article-title":"Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets \u2013 results of one year follow-up","volume":"153","author":"Marek-Trzonkowska","year":"2014","journal-title":"Clin Immunol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"B139","doi-asserted-by":"publisher","first-page":".e1201","DOI":"10.1053\/j.gastro.2012.07.116","article-title":"Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn\u2019s disease","volume":"143","author":"Desreumaux","year":"2012","journal-title":"Gastroenterology"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol Ther"},{"key":"B141","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/ajt.14185","article-title":"Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection","volume":"17","author":"Boardman","year":"2017","journal-title":"Am J Transplant"},{"key":"B142","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/ajt.14175","article-title":"Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am J Transplant"},{"key":"B143","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood-2016-07-727834","article-title":"FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII","volume":"129","author":"Yoon","year":"2017","journal-title":"Blood"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"B145","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1111\/ajt.14415","article-title":"Polyclonal regulatory T cell therapy for control of inflammation in kidney transplants","volume":"17","author":"Chandran","year":"2017","journal-title":"Am J Transplant"},{"key":"B146","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.jcyt.2016.05.009","article-title":"Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy","volume":"18","author":"Mock","year":"2016","journal-title":"Cytotherapy"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00153\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T21:14:12Z","timestamp":1693516452000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00153\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,5]]},"references-count":147,"alternative-id":["10.3389\/fimmu.2018.00153"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00153","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,5]]},"article-number":"153"}}